| Old Articles: <Older 3151-3160 Newer> |
|---|
 |
Managed Care
September 2006
Thomas Morrow |
Remarkable Work Went Into Designing the New HPV Vaccine The recently approved human papillomavirus vaccine is a prime example of how science is beating back the advance of old diseases.   |
Managed Care
September 2006 |
Payers, Consumers Benefit as Patents Expire The generic drug market seems ready to explode, according to reports from IMS Health and the Generic Pharmaceuticals Association. |
The Motley Fool
September 29, 2006
Brian Lawler |
Pfizer Helps France Kick Butts Europe approves the pharmaceutical's new drug to help smokers quit. Activities like this drug approval, and the molecule licensing earlier this week from privately held Quark Biotech, should eventually reignite Pfizer's moribund revenue growth. |
The Motley Fool
September 29, 2006
Jim Gillies |
A Health-Care Stock to Avoid Investors, before you leap in, keep in mind that not all health-care businesses are potential gold mines. Enter PolyMedica. |
The Motley Fool
September 29, 2006
Brian Lawler |
The Long Road Ahead for ViroPharma Faced with the threat of generic competition, the company focuses its efforts on a new drug. ViroPharma investors should watch intently. |
The Motley Fool
September 28, 2006
Brian Lawler |
Amgen Secures Its Future FDA approval for the company's colorectal cancer drug is good news for its future prospects. Investors, take note. |
The Motley Fool
September 28, 2006
Brian Lawler |
Myriad Moves Forward The biotech's new cancer candidate passes phase 1 trials. Investors should take note, and make room for Myriad on their radar screens. |
The Motley Fool
September 28, 2006
Brian Lawler |
Exelixis' Growing Share Count The developing biopharmaceutical company announces a share offering. |
The Motley Fool
September 27, 2006
Brian Lawler |
One Step Forward for InterMune The company's lead drug will enter phase 1 trials, bringing potential good fortune to investors. |
The Motley Fool
September 27, 2006
Brian Lawler |
Enormous Interest in AnorMED Genzyme and Millenium vie to purchase the Canadian biotech. Shares of AnorMED currently trade for more than $12 a share. |
| <Older 3151-3160 Newer> Return to current articles. |
